Possible scenario
Rapid US Uptake
40% Chance
Onswik becomes the first broadly used once-weekly basal insulin in the US, benefiting from convenience, physician familiarity with Lilly's diabetes franchise, and the prior Phase 3 safety data. The most likely positive case is not a whole-market shock, but a material company-level gain for Eli Lilly and competitive pressure on Novo Nordisk and Sanofi.
Tickers
- LLY+4.6%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.